Table 2. Adverse events in patients with... | American Society of Hematology

Table 2.

Adverse events in patients with MF/SS treated with alemtuzumab

Patient no.	Cardiac risks		EF, %					Previously received ANTH	Died within 30 d of discontinuing alemtuzumab
Patient no.	Cardiac risks			Adverse event(s)	Before	During	After	Previously received ANTH	Died within 30 d of discontinuing alemtuzumab
1	—	Atrial fibrillation	—	55	—	No	No
2	—	CHF/LV dysfunction, ventricular tachycardia	60	29	39	Yes	No
3	CAD	Anasarca/infection	—	50	—	No	Yes
4	HTN	Infection	—	55	—	Yes	Yes
5	—	CHF/infection	—	55	—	No	No
6	—	CHF/LV dysfunction	60	20	55	No	No
7*	HTN	Profound hypotension	60	—	—	No	Yes
8*	HTN/DM	CHF/LV dysfunction	59	15	30	Yes	No

Patient no.	Cardiac risks		EF, %					Previously received ANTH	Died within 30 d of discontinuing alemtuzumab
Patient no.	Cardiac risks			Adverse event(s)	Before	During	After	Previously received ANTH	Died within 30 d of discontinuing alemtuzumab
1	—	Atrial fibrillation	—	55	—	No	No
2	—	CHF/LV dysfunction, ventricular tachycardia	60	29	39	Yes	No
3	CAD	Anasarca/infection	—	50	—	No	Yes
4	HTN	Infection	—	55	—	Yes	Yes
5	—	CHF/infection	—	55	—	No	No
6	—	CHF/LV dysfunction	60	20	55	No	No
7*	HTN	Profound hypotension	60	—	—	No	Yes
8*	HTN/DM	CHF/LV dysfunction	59	15	30	Yes	No

EF indicates ejection fraction; ANTH, anthracyclines; —, not done; CHF, congestive heart failure; LV, left ventricular; CAD, coronary artery disease; HTN, hypertension; and DM, diabetes mellitus.

View Large

This Feature Is Available To Subscribers Only